In Brief: Rybelsus R2 Rebranded as Ozempic

Oral semaglutide 1.5-, 4-, and 9-mg tablets, which were previously approved by the FDA (but never marketed) as the R2 formulation of Rybelsus, have now been approved as Ozempic.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2026-04-13
DOI
https://doi.org/10.58347/tml.2026.1752f
Primary Topic
Origins and Evolution of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Brief: Rybelsus R2 Rebranded as Ozempic

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Origins and Evolution of Life
article

In Brief: Rybelsus R2 Rebranded as Ozempic

article en

Abstract

Oral semaglutide 1.5-, 4-, and 9-mg tablets, which were previously approved by the FDA (but never marketed) as the R2 formulation of Rybelsus, have now been approved as Ozempic.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 68(1752)
Openalex Percentile: Top 15%
Origins and Evolution of Life
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In Brief: Rybelsus R2 Rebranded as Ozempic · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2026) | TGRS Research Map | TGRS